Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Slides:

Advertisements

Similar presentations

David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]

Advertisements

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Figure 1 Ischaemic endpoints

Figure 4 Activation of clopidogrel via cytochrome P450

Baseline characteristics of patients

Terms of Use. Terms of Use.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Consolidated Standards of Reporting Trials diagram

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Coronary revascularisation rate (total 5

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Tornado diagram of one-way deterministic sensitivity analysis.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Masashi Maeda et al. Heart Asia 2013;5:7-14

Figure 9 Management of atrial fibrillation

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots for randomised and cluster randomised controlled trials from Cochrane review Biomarkers as point-of-care tests to guide prescription of antibiotics.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Hierarchical clustering analysis of 7785 genes (genes with a log-ratio variation in the 25th centile and >5% missing data were excluded) (A) A heat map.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Different behaviours between group 1 and group 2 patients of the mean and SD of Δ for low frequency (LF), high frequency (HF) and total power (TP) calculated.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Correlation of calibrated integrated backscatter (cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis (B) in patients undergoing coronary.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Bland-Altman plots for intra and inter observer variability for the assessment of total Agatston score for patients with a calcium score less than 1000.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Decision tree (using the CHAID algorithm) for predicting participation in a cardiac prevention and rehabilitation programme (CPRP) among 420 Jewish and.

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Forest plot of the association between early coronary angiography and survival in patients with out-of-hospital cardiac arrest A: including unadjusted.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Calculating the overall accuracy in different samples using the V-plot

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Forest plot illustrating the risk ratio of major bleeding

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Forest plot of major bleeding: the measure of the effect of morphine versus nonmorphine on major bleeding in each study was plotted using OR and 95% CI.

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Performance of the Manchester Acute Coronary Syndromes decision rule in the derivation study. Performance of the Manchester Acute Coronary Syndromes decision.

Presentation transcript:

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A) definite stent thrombosis; (B) need for revascularisation; (C) cerebrovascular accidents; (D) acute corona... Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A) definite stent thrombosis; (B) need for revascularisation; (C) cerebrovascular accidents; (D) acute coronary syndromes. Rhanderson N Cardoso et al. Open Heart 2015;2:e000248 ©2015 by British Cardiovascular Society